VXRT

Vaxart Inc

$0.61
0.04 (7.02%) Today
Compare VXRT
Market Cap
$136M+34.4%
Revenue (TTM)
$255.38M+439.3%
Net Income (TTM)
$37.09M
EPS (TTM)
0.15
Shares Out
241.97M
P/E Ratio
3.52
Forward P/E
2.36
Open
$0.61
Previous Close
$0.57
Day Range
$0.58 – $0.62
52-Week Range
$0.26 – $0.84
Beta
1.15
Volume
74.33K
Avg Volume
466.64K
Analyst Rating
Buy
Exchange
OTC MARKETS

About VXRT

Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.

Related

News